申请人:TAISHO PHARMACEUTICAL CO. LTD
公开号:EP0870758A1
公开(公告)日:1998-10-14
The present invention relates to an optically active, substituted phenylalkylamine derivative represented by Formula [1]:
wherein A is a substituted or non-substituted phenyl or thienyl; X1 is hydrogen, halogen, hydroxyl or a substituted or non-substituted C1-5 alkoxy; R1 and R2 are equally or differently hydrogen, C1-7 alkyl, C3-7 alkenyl or C3-7 alkynyl; R3 is C1-10 alkyl, C2-10 alkenyl or C2-10 alkynyl; n is an integer from 2 to 5; and m is an integer from 1 to 4,
or a pharmaceutically acceptable salt thereof, and pharmaceutical use of such compound or salt. The compound of the invention is excellent in sigma 1 receptor antagonism and useful for treating schizophrenia, depression, anxiety, cerebrovascular diseases/senile troublesome behaviors, and cognitive dysfunctions and motor dysfunctions such as Alzheimer's disease, Parkinson's disease and Huntington's disease which are neurodegenerative diseases. Further, the compound of the invention is also useful for treating dependence resulted from drug abuse.
本发明涉及一种由式[1]表示的具有光学活性的取代苯基烷基胺衍生物:
其中 A 是取代或非取代的苯基或噻吩基;X1 是氢、卤素、羟基或取代或非取代的 C1-5 烷氧基;R1 和 R2 相同或不同地是氢、C1-7 烷基、C3-7 烯基或 C3-7 烷炔基;R3 是 C1-10 烷基、C2-10 烯基或 C2-10 烷炔基;n 是 2 至 5 的整数;m 是 1 至 4 的整数、
或其药学上可接受的盐,以及这种化合物或盐的药物用途。本发明化合物具有优异的σ1受体拮抗作用,可用于治疗精神分裂症、抑郁症、焦虑症、脑血管疾病/躁狂症、认知功能障碍和运动功能障碍,如阿尔茨海默病、帕金森病和亨廷顿病等神经退行性疾病。此外,本发明的化合物还可用于治疗药物滥用导致的依赖性。